Tonix Pharmaceuticals (NASDAQ: TNXP) and Innovus Pharmaceuticals (OTCMKTS:INNV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Volatility and Risk

Tonix Pharmaceuticals has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 3.39, indicating that its share price is 239% more volatile than the S&P 500.


This table compares Tonix Pharmaceuticals and Innovus Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals N/A -78.25% -73.14%
Innovus Pharmaceuticals -102.95% -330.39% -72.75%

Analyst Recommendations

This is a summary of recent recommendations for Tonix Pharmaceuticals and Innovus Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals 0 1 4 0 2.80
Innovus Pharmaceuticals 0 0 0 0 N/A

Tonix Pharmaceuticals presently has a consensus price target of $8.33, indicating a potential upside of 142.95%. Given Tonix Pharmaceuticals’ higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Innovus Pharmaceuticals.

Valuation and Earnings

This table compares Tonix Pharmaceuticals and Innovus Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tonix Pharmaceuticals N/A N/A -$38.84 million ($3.38) -1.01
Innovus Pharmaceuticals $4.82 million 3.04 -$13.70 million ($0.06) -1.48

Innovus Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals. Innovus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

17.5% of Tonix Pharmaceuticals shares are held by institutional investors. 4.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 19.1% of Innovus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


Innovus Pharmaceuticals beats Tonix Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.